GovChime
Notice ID: 5816fd15c86b44d69534709710fa32ffPresolicitationArchived

NOI to Sole Source to QuVa Pharma, Inc.

Archived on May 21, 2026. Original response deadline: . Full description on SAM.gov.

Overview

Response deadline
9:00 AM EDT
Posted
May 1, 2026
Notice type
Presolicitation
Set-aside
No Set aside used
NAICS
325412: Pharmaceutical Preparation Manufacturing
Agency
Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH

Notice details

Office
NATIONAL INSTITUTES OF HEALTH OLAO
Place of performance
Bethesda, Maryland, 20892
Last updated
Oct 30, 2026
First published
Last updated on SAM.gov

Identifiers

Solicitation number
NOI-OD-26-000038
Notice ID
5816fd15c86b44d69534709710fa32ff

Description

The purpose of this acquisition is to purchase 503b compounded Intravenous (IV) Narcotics for patient care. Market research has been conducted with only two responses, from QUVA, the known Compounder and distributor for these IV narcotics.  Through trade shows, continuous learning seminars and trade journals, the CC Pharmacy Department stays abreast of the industry and is current on the availability of singular distribution outlets for these medications.

•             Product Service Code: 6515 – Medical and Surgical Instruments, Equipment, and Supplies

•             NAICS Code: 325412 – Pharmaceutical Preparation Manufacturing

•             Place of Performance: NIH Clinical Center, Bethesda, MD 20892 USA

POTS: 26-000038

Description:

This is a notice of intent, not a request for a quotation.  A solicitation document will not be issued, and quotations will not be requested.

The National Institutes of Health (NIH) intends to award a one-year contract to QuVa Pharma, Inc., located at 3 Sugar Creek Center Boulevard, Sugarland, TX 77478, on a firm fixed price sole source award basis for the purchase of 503b compound Intravenous (IV) Narcotics for patient care.

The proposed vendor, QuVa Pharma Inc., is the Original Manufacturer and has not designated other distributors of IV narcotics in the U.S.

This acquisition is being conducted using policies unique to the Federal Acquisition Regulation (FAR) Part 13 – Simplified Acquisition Procedures, Subpart 13.106-1(b)(1), For purchases not exceeding the simplified acquisition threshold (SAT), contracting officers may solicit from one source if the contracting officer determines that the circumstance of the contract action deem only one source reasonably available.  Contracts awarded using FAR Part 13-Simplified Acquisition Procedures are exempt from the requirements of FAR Part 6-Competition Requirements.

The determination by the Government not to compete the proposed requirement based upon responses to this notice is solely within the discretion of the Government.

Comments to this announcement, referencing this posting number, may be submitted to the NIH, Clinical Center, Office of Purchasing and Contracts, prior to the closing date specified in this announcement, to the attention of Huda Malik, Contract Specialist via email to huda.malik@nih.gov by May 6, 2026 at 9 am EST.

Full description on SAM.gov

Award Overview

No prior contract identified

No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.

Contacts

Contracting Officer

Primary Contact

Documents

Files (1)

  • JOFOC QUVA 503B IV NARCOTICS 04.2026_FG.pdf

    671 KBAdded in Presolicitation version 3Posted
    Download

Lifecycle

  1. 3
    Version 3PresolicitationArchivedCurrent

    NOI to Sole Source to QuVa Pharma, Inc.

    Notice 5816fd15c86b44d69534709710fa32ff on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline

Additional Details

Solicitation Number

NOI-OD-26-000038

Archive Date

May 21, 2026

Office Address

BETHESDA, MD, 20892